5245582025-07-012025-09-305245582025-09-305245582025-03-315245582025-04-012025-09-305245582025-07-012025-09-30in-capmkt:OtherExpenses1Member5245582025-07-012025-09-30in-capmkt:OtherExpenses2Member5245582025-04-012025-09-30in-capmkt:OtherExpenses1Member5245582025-04-012025-09-30in-capmkt:OtherExpenses2Member5245582025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15245582025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss25245582025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15245582025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss25245582025-07-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15245582025-04-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares524558NEULANDLABNOTLISTEDINE794A01010Neuland Laboratories LimitedMain BoardEquity2025-04-012026-03-312025-11-072025-10-24INRLakhsQuarterlySecond quarterSingle segmentManufacturing of Active Pharmaceuticals2025-11-0714:35:002025-11-0716:05:00trueCash Flow IndirectNot applicable2025-07-012025-09-30UnauditedConsolidated514273100017997000516072800022764000000-44031000080372300053671000225415000947464000386636300012943650000129436500032512500070100032582600009685390000000968539000-108300096745600000001290050001075.4975.490075.4975.491. The financial results for the quarter and half year ended September 30, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 07, 2025. The Statutory auditor have issued an unmodified opinion in respect of the limited review for the quarter and half year ended September 30, 2025. <BR> <BR> 2. The financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. <BR> <BR> 3. The consolidated financial results include results of the following wholly owned subsidiaries: <BR> (a) Neuland Laboratories Inc., USA <BR> (b) Neuland Laboratories KK., Japan. <BR> <BR> 4. The operations of the Company are predominantly related to the manufacture and sale of active pharmaceutical ingredients and allied services. As such there is only one primary reportable segment as per Ind AS 108 "Operating Segments". <BR> <BR> 5. During the previous year, the Company has fully transferred an investment property located in Nanakramguda, Hyderabad, Telangana, through perpetual lease, resulting in total profit of Rs. 7,640.36 lakhs (For the Half year ended September 30, 2024: Rs. 2,062.56 lakhs) being the profit is exceptional in nature, it has been disclosed as a separate line item. <BR> <BR> 6. The EPS for quarters has not been annualised.2025-04-012025-09-30UnauditedConsolidated807025800096556000816681400038912040000-91967500015383740009952000042731000016600120006696745000147006900001470069000368793000-62630003625300000110753900000001107539000-91000110744800000001290050001086.3286.320086.3286.32Manufacturing Expenses459562000Other Expenses487902000Manufacturing Expenses853310000Other Expenses8067020007875879000139953500002794610000591640002942700000152890000011472900013001800003960420001268467500054789820001121524000440921400041341800015221000001094220006205788000097089400012655664000002534033900012900500016072546000162015510000162015510008922430000001011057000190330000071692000720976000002695968000709629000135442000276279500028982370008852560004493122000192471400024477000507000064428200000091387880002534033900099520000-1621413000-12318900000-2763800000-21119000-145815000034046800001094453000042731000003505000-4442000-897700000697530000518590000-44697000000140650000-1438311000317580000003992260000-367468000000000004384000165415900000053301000000000000000006418800001116938000-5219500000000000047740300023451600084430001539590009978900000-19304000-9087220002836000-9058860001319304000413418000Re-measurement gain/(loss) on defined benefit plans-3911000Equity instruments through other comprehensive income0-3911000Re-measurement gain/(loss) on defined benefit plans-3911000Equity instruments through other comprehensive income0-3911000-984000-984000Exchange differences in translating the financial statements of foreign operations18440001844000Exchange differences in translating the financial statements of foreign operations2836000283600000-1083000-91000